Today: 4 June 2026
Browse Category

NASDAQ:EDIT 2 November 2025 - 4 June 2026

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics shares soared 11.7% to $58.15 after presenting at the Jefferies Global Healthcare Conference, with sector momentum lifting gene-editing stocks and the SPDR S&P Biotech ETF up 3.0%. Casgevy, its key sickle cell therapy, posted $43 million Q1 revenue, but a $122.9 million net loss and biotech risks mean the rally hinges on investor appetite and upcoming clinical updates.
4 June 2026
·······
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics shares fell 4.3% to $54.00 after a filing showed CFO Raju Prasad exercised and sold 29,700 shares under a preset trading plan. The move comes ahead of the company’s Jan. 12 slot at the J.P. Morgan Healthcare Conference and an expected mid-February earnings report. Gene-editing peers also traded lower. CASGEVY revenue and rollout remain key investor focus.
9 January 2026
·······
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics shares closed down 1.4% at $52.44 on Dec. 31, the final trading day of 2025. U.S. markets were shut Jan. 1 for New Year’s. Investors are watching for early-2026 updates on Casgevy’s rollout and the next earnings schedule as trading resumes Jan. 2. Biotech ETFs were little changed in light year-end trading.
2 January 2026
······
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

The FDA will announce a new fast-track approval process for personalized gene-editing therapies in early November, sending CRISPR Therapeutics shares up 8% and Editas up 12%. CRSP reported over 90% mRNA correction in preclinical CTX460 data and will present Phase 1 CTX310 results at the AHA conference Nov. 8. Intellia paused a TTR amyloidosis trial after a liver injury, causing its stock to fall 46%.
2 November 2025
······

Stock Market Today

  • Uber Stock Falls 12% YTD: Should Investors Hold or Sell?
    June 4, 2026, 1:47 PM EDT. Uber Technologies shares have declined 12.3% year-to-date, underperforming the Zacks Internet-Services industry and the S&P 500 index. Rival Lyft has seen even steeper losses. Uber's diversification beyond ride-hailing into food delivery and freight, along with geographic expansion, supports growth potential. Recent partnerships, such as with Ulta Beauty to expand Uber Eats' product offerings, aim to boost revenue. Despite geopolitical tensions, Uber's gross bookings-a key measure of transaction volume-rose 20% in Mobility and 23% in Delivery in Q1 2026, signaling robust demand. Investors face a choice between selling amid near-term weakness or holding for long-term growth driven by strategic expansion and solid booking trends.

Latest articles

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics Jumps 12% in New York Trading

4 June 2026
CRISPR Therapeutics shares soared 11.7% to $58.15 after presenting at the Jefferies Global Healthcare Conference, with sector momentum lifting gene-editing stocks and the SPDR S&P Biotech ETF up 3.0%. Casgevy, its key sickle cell therapy, posted $43 million Q1 revenue, but a $122.9 million net loss and biotech risks mean the rally hinges on investor appetite and upcoming clinical updates.
Reddit Stock Is Running Hot Again. The Ad Bet Behind RDDT’s Sudden Jump

Reddit Stock Is Running Hot Again. The Ad Bet Behind RDDT’s Sudden Jump

4 June 2026
Reddit shares surged 6.3% to $180.19 Thursday after Loop Capital reiterated a Buy rating with a $260 target and investors responded to new automated app-ad tools; first-quarter revenue jumped 69% to $663 million, but risks remain as Reddit warns that search changes or weaker ad budgets could hurt traffic and results.
Keel Slides After AI Data Center Run-Up; Power Bottleneck in Focus

Keel Slides After AI Data Center Run-Up; Power Bottleneck in Focus

4 June 2026
Keel shares slipped 1.7% to $6.05 after a rapid surge of 19% in a week and 98% in a month, as investors focus on whether the company can secure AI data-center leases at its power-rich sites; first-quarter revenue fell 23% to $37 million with a $98 million operating loss, and delays or permit issues could threaten the stock’s momentum.
AT&T falls as SpaceX threat renews broadband concerns

AT&T falls as SpaceX threat renews broadband concerns

4 June 2026
AT&T shares plunged 3.7% to $22.69 after Oppenheimer downgraded the stock, warning SpaceX’s Starlink could disrupt the $1.6 trillion U.S. communications market and threaten broadband and mobile subscriber growth; the drop came as the Supreme Court upheld FCC fines against AT&T and as SpaceX moves toward a public listing, intensifying investor focus on broadband competition.
Go toTop